Table 2 hASH1 protein expression in prostate adenocarcinoma and correlation with clinicopathological features and neuroendocrine differentiation
From: Human ASH1 expression in prostate cancer with neuroendocrine differentiation
Characteristic | No. of patients | hASH1 IHC | P-value | |
|---|---|---|---|---|
| Â | Â | Positive | Negative | Â |
Total cases | 80 | 21 | 59 | Â |
Age (mean 67.9 years) | Â | Â | Â | Â |
 ≤65 | 28 | 5 | 23 |  |
 >65 | 52 | 16 | 36 | P=0.324 |
Gleason score | Â | Â | Â | Â |
≤6 | 28 | 4 | 24 |  |
 7–10 | 37 | 7 | 30 | P=0.873 |
 NA* | 15 | — | — |  |
Primary tumor stage | ||||
 pT2 | 35 | 3 | 32 |  |
 pT3 | 26 | 8 | 18 |  |
 NA | 19 | — | — | P=0.058 |
Preoperative serum PSA (ng/ml) | ||||
 <10 | 26 | 4 | 22 |  |
 10–20 | 20 | 3 | 17 |  |
 >20 | 7 | 3 | 4 | P=0.219 |
NA | 27 | — | — |  |
Presence of NE differentiation (CgA score) | ||||
 PC-nonNE (score 0) | 25 | 1 | 24 |  |
 PC-NE/untreated (score 1) | 20 | 3 | 17 |  |
 PC-NE/untreated (score 2) | 20 | 7 | 13 | P=0.02 |
Endocrine therapy administration | ||||
 PC-NE/untreated | 40 | 10 | 30 |  |
 PC-NE/treated | 15 | 10 | 5 | P=0.01 |
